Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Summary

Multiple myeloma remains incurable disease in most patients . Cellular immunotherapy using dendritic cells is emerging as a useful immunotherapeutic modality to treat multiple myeloma. Vax-DC/MM is an potent immunotherapeutic agent generated by dendritic cells loaded with the ultraviolet B-irradiated autologous human myeloma cells. The main purpose of this study is to examine the safety and efficacy of Vax-DC/MM in patients with relapsed or refractory multiple myeloma.

Timeline

Start

2013-10

Primary completion

2015-10

Completion

—

Drugs

Indications